NURPF 13.03 Neuren Pharmaceuticals Limited
| Range: | 6.17-17.205 | Vol Avg: | 445 | Last Div: | 0 | Changes: | 1.23 |
| Beta: | 2.13 | Cap: | 1.15B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Nov 04 2009 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | NZNEUE0001S8 | Country: | AU | ||
| CEO: | Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | Website: | https://www.neurenpharma.com | ||||
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow